| Dose level | Dose of drug: crizotinib | Dose of drug: pembrolizumab | Number enrolled | Number evaluable for toxicity |
|---|---|---|---|---|
| 0 | 250 mg twice daily | 200 mg every 3 weeks | 2 | 2 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.